EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

From bench to clinic: the development of VLA1553/IXCHIQ, a live-attenuated chikungunya vaccine

Lin H Chen, Andrea Fritzer, Romana Hochreiter, Katrin Dubischar, Stéphanie Meyer

Journal of Travel Medicine · 19.10.2024 · 31 (7)

DOI: 10.1093/jtm/taae123 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Travel Medicine, online erschienen am 10.09.2024. Verfasst von Lin H Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases and Travel Medicine, Mount Auburn Hospital, 330 Mt Auburn St, Cambridge, MA 02138, USA. Hauptthemen laut MEDLINE: Vaccines, Attenuated, Chikungunya Fever, Chikungunya virus, Viral Vaccines. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coalition for Epidemic Preparedness Innovation and EU Horizon 2020.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Over the past 20 years, over 5 million cases of chikungunya, a mosquito-transmitted viral disease, have been reported in over 110 countries. Until recently, preventative strategies for chikungunya were largely ineffective, relying on vector control and individual avoidance of mosquito bites.

Methods

This review outlines the preclinical and clinical efficacy and safety data that led to the approval of VLA1553 (IXCHIQ®), a live-attenuated vaccine against chikungunya disease. It also describes the innovative development pathway of VLA1553, based on an immunological surrogate of protection, and discusses ongoing and future post-licensure studies.

Results

In mice and non-human primate models, VLA1553 elicited high titres of neutralizing antibodies, conferred protection against wild-type chikungunya virus challenge and raised no safety concerns. A Phase 1 clinical trial of VLA1553 demonstrated 100% seroconversion among 120 healthy participants, with sustained neutralizing antibody titres after 12 months. These results and determination of a surrogate marker of protection led to advancement of VLA1553 directly into Phase 3 clinical development, as agreed with the US Food and Drug Administration (FDA) and the European Medicines Agency. The pivotal Phase 3 trial met its primary immunogenicity endpoint, achieving seroprotective levels based on immuno-bridging in baseline seronegative participants 28 days post-vaccination. These findings enabled submission of a Biologics Licence Application to the FDA for accelerated approval of VLA1553 in the US for adults aged ≥18 years. Ongoing and planned studies will confirm the clinical efficacy/effectiveness and safety of VLA1553 in adults and younger individuals, and will generate data in chikungunya endemic countries that have the highest unmet need.

Conclusion

VLA1553 is the first vaccine approved for the prevention of chikungunya disease in adults, following accelerated development based on a serological surrogate marker of protection. VLA1553 adds to strategies to reduce the spread and burden of chikungunya in endemic populations and travellers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vaccines, AttenuatedChikungunya FeverChikungunya virusViral VaccinesHumansAnimalsAntibodies, NeutralizingMice

Stichwörter der Autor:innen

VLA1553arboviruschikungunyaimmunogenicitysafetysurrogate of protectionvaccine

Substanzen

Vaccines, AttenuatedViral VaccinesAntibodies, Neutralizing

Autor:innen und Institutionen

  • Department of Medicine, Division of Infectious Diseases and Travel Medicine, Mount Auburn Hospital, 330 Mt Auburn St, Cambridge, MA 02138, USA.
  • Faculty of Medicine, Harvard Medical School, 25 Shattuck St, Boston, MA 02115, USA.
  • Pre-Clinical Vaccine Development Department, Valneva Austria GmbH, Campus-Vienna-Biocenter 3, 1030 Vienna, Austria.
  • Clinical Serology Department, Valneva Austria GmbH, Campus-Vienna-Biocenter 3, 1030 Vienna, Austria.
  • R&D Management, Valneva Austria GmbH, Campus-Vienna-Biocenter 3, 1030 Vienna, Austria.
  • Corporate Medical Affairs, Valneva SE, Ilot Saint-Joseph Bureaux Convergence, 12 ter Quai Perrache Bâtiment A, 69002 Lyon, France.

Förderung

  • Coalition for Epidemic Preparedness Innovation and EU Horizon 2020

Zitieren

APA

Chen, L. H., Fritzer, A., Hochreiter, R., Dubischar, K., & Meyer, S. (2024). From bench to clinic: the development of VLA1553/IXCHIQ, a live-attenuated chikungunya vaccine. Journal of Travel Medicine, 31(7). https://doi.org/10.1093/jtm/taae123

Vancouver

Chen LH, Fritzer A, Hochreiter R, Dubischar K, Meyer S. From bench to clinic: the development of VLA1553/IXCHIQ, a live-attenuated chikungunya vaccine. Journal of Travel Medicine. 2024;31(7). doi:10.1093/jtm/taae123

BibTeX
@article{Chen2024,
  author = {Chen, Lin H and Fritzer, Andrea and Hochreiter, Romana and Dubischar, Katrin and Meyer, Stéphanie},
  title = {From bench to clinic: the development of VLA1553/IXCHIQ, a live-attenuated chikungunya vaccine},
  journal = {Journal of Travel Medicine},
  year = {2024},
  volume = {31},
  number = {7},
  doi = {10.1093/jtm/taae123}
}
Kostenlos starten →